NCT03651921

Brief Summary

The adjusted Cancer Thriving and Surviving Program (CTS) for women with breast cancer living in Switzerland (CTS-BC-CH) is a course of 7 weekly sessions of 2.5 - 3 hours led by trained peer-leaders (women with breast cancer experience). This pilot study aims to explore the reach of the CTS-BC-CH program (integrated into the clinical pathway) and to investigate its preliminary effectiveness with regard to Swiss breast cancer patients' self-efficacy and self-management.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2017

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 12, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 1, 2018

Completed
4 months until next milestone

First Posted

Study publicly available on registry

August 29, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2019

Completed
Last Updated

August 24, 2020

Status Verified

August 1, 2020

Enrollment Period

1.7 years

First QC Date

May 1, 2018

Last Update Submit

August 21, 2020

Conditions

Keywords

Breast CancerSelf-ManagementCancer Survivorship

Outcome Measures

Primary Outcomes (2)

  • Reach of intervention assessed by ratio of eligible patients vs. participating patients

    21 weeks after baseline

  • Changes in self-management skills assessed by heiQ

    Assessed by the Health Education Impact Questionnaire (heiQ)

    Change from baseline to 20 weeks after baseline

Secondary Outcomes (5)

  • Change in patient-reported self-efficacy assessed by SES6G

    Change from baseline to 20 weeks after baseline

  • Change in patient-reported health literacy assessed by HLS-EU-Q6

    Change from baseline to 20 weeks after baseline

  • Change in patient-reported symptom burden assessed by BCPT Symptom Scales

    Change from baseline to 20 weeks after baseline

  • Change in patient-reported health service navigation assessed by heiQ

    Change from baseline to 20 weeks after baseline

  • Change in nurse-reported self-efficacy and self-management support practices assessed by SEPSS

    Change from baseline to 30 weeks after baseline

Study Arms (2)

Usual care

NO INTERVENTION

Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).

Usual care and CTS-BC-CH

EXPERIMENTAL

CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.

Behavioral: CTS-BC-CH

Interventions

CTS-BC-CHBEHAVIORAL

CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants. Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making.

Usual care and CTS-BC-CH

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsOnly female breast cancer patients or female breast care nurses.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Inclusion breast cancer patients * female gender * written informed consent * aged 18 years or older * diagnosed with an early stage breast cancer (stage 0, stage I, stage IIA, stage IIB, and stage IIIA breast cancers) * completed primary therapy (i. e. surgery, chemotherapy and/or radiation therapy) * at the beginning of follow-up care (including long-term endocrine therapy or targeted therapy) * free of recurrence * mentally able to participate, assessment of the psychological state performed by the responsible psychologist/psycho-oncologist in the breast center * treated in the participating breast center Inclusion course leaders * female gender * written informed consent * aged 18 years or older * diagnosed with an early stage breast cancer (stage 0, stage I, stage IIA, stage IIB, and stage IIIA breast cancers) * \> than 2 years post diagnosis * free of recurrence * mentally able to participate, assessment of the psychological state performed by the responsible psychologist/psycho-oncologist in the breast center * treated in the participating breast center * willing to participate in a course leaders training Exclusion breast cancer patients and course leaders * participation in another psycho-social intervention study * known illiteracy (reading and writing difficulties) * lack of language proficiency (German) Inclusion breast care nurses for CTS-BC-CH implementation * female gender * employed at breast care center \> 1 year * participation in 4-days CTS-BC-CH course leader training Inclusion breast care nurses for evaluating self-management support practices * nurses: graduated with a nurses diploma \> 1 year of breast cancer care experience

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (2)

University Hospital Basel

Basel, 4031, Switzerland

Location

University Inselspital Bern

Bern, 3010, Switzerland

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Manuela Eicher, Prof. Dr.

    Institute of Higher Education and Reserach in Health Care - IUFRS University of Lausanne and University Hospital of Lausanne

    STUDY DIRECTOR
  • Joerg Haselbeck, Dr.

    Swiss Cancer League Berne; Formely: Careum Stiftung, Kompetenzzentrum Patientenbildung

    STUDY DIRECTOR
  • Karin Ribi, Dr. phil.

    International Breast Cancer Study Group (IBCSG)

    STUDY CHAIR
  • Corinne Urech, Dr. phil.

    University Hospital, Basel, Switzerland

    STUDY CHAIR
  • Karin Holm

    Patient Advocats for Cancer Reserach and Treamtment (Association PARCT)

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 1, 2018

First Posted

August 29, 2018

Study Start

December 12, 2017

Primary Completion

August 15, 2019

Study Completion

August 15, 2019

Last Updated

August 24, 2020

Record last verified: 2020-08

Locations